Detalhe da pesquisa
1.
TGFß attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Nature
; 554(7693): 544-548, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29443960
2.
In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales.
Brief Bioinform
; 22(3)2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32940337
3.
Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens.
Prostate
; 82(9): 993-1002, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35435276
4.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Proc Natl Acad Sci U S A
; 115(43): E10119-E10126, 2018 10 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30297397
5.
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Lancet
; 391(10122): 748-757, 2018 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29268948
6.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet
; 389(10064): 67-76, 2017 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27939400
7.
Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer.
JCO Precis Oncol
; 8: e2300562, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547419
8.
Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.
Drug Metab Dispos
; 41(12): 2104-13, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24041744
9.
Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI).
Clin Cancer Res
; 28(18): 4083-4091, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877091
10.
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.
Nat Med
; 28(1): 144-153, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35013615
11.
A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 27(17): 4746-4756, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34108181
12.
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Clin Cancer Res
; 27(12): 3360-3369, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33568344
13.
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.
Blood
; 112(3): 711-20, 2008 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18497318
14.
Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer.
Cancer Immunol Res
; 8(7): 844-850, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32321776
15.
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Nat Med
; 26(5): 693-698, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32405063
16.
PD-L1 and tumor-associated macrophages in de novo DLBCL.
Blood Adv
; 3(4): 531-540, 2019 02 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770362
17.
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
Nat Med
; 27(3): 560, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33547461
18.
Transcriptional-based screens for pathway-specific, high-throughput target discovery in endothelial cells.
J Biomol Screen
; 9(8): 704-11, 2004 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-15634797